Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01838044CT.gov Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Neuropathy, Painful
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Approved | BB · 65 |
| Pregabalin | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | P4 | BB |
| Nepenthe | Nova Scotia Health Authority | P4 | BB |
| Naltrexone | Emory University | P4 | BB |
| Fentanyl | Cephalon | P3 | B |
| Incobotulinumtoxina | Merz Therapeutics GmbH | P2 | B |
| Lacosamide | Danish Pain Research Center | P2 | B |
| Valproic Acid | University Hospital, Bordeaux | P2/3 | CCC |
| 3,4-methylenedioxymethamphetamine | Unity Health Toronto | P2 | CCC |
+11 more in the Neuropathy, Painful cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Celecoxib in Neuropathy, Painful. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-neuropathy-painful
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →